Full Transcript: Medpace Hldgs Q2 2026 Earnings Call

On Thursday, Medpace Hldgs (NASDAQ: MEDP ) discussed second-quarter financial results during its earnings call.

The full transcript is provided below.

This transcript is brought to you APIs.

For real-time access to our entire catalog, please visit for a consultation.

The full earnings call is available at Summary Medpace Hldgs reported Q2 2026 revenue of $707.3 million, a 17.2% year-over-year increase, with a six-month revenue of $1.41 billion, up 21.7%.

Net income for Q2 was $121.4 million, a 34.5% increase from the previous year, driven by a lower tax rate and higher interest income.

The company updated its 2026 guidance, expecting total revenue between $2.805 billion and $2.885 billion, with an EBITDA range of $618 million to $642 million.

Net new business awards increased by 28.2% year-over-year to $795.7 million, with a book-to-bill ratio of 1.13, indicating strong demand.

Cancellations decreased significantly, benefiting net bookings, while oncology bookings saw a substantial increase, surpassing metabolic programs.

Management highlighted an improved business environment with strong RFPs and a constructive outlook for 2027, despite uncertainties in cancellation trends.

The company's headcount growth is expected to continue, with significant expansion in the US and Asia Pacific regions, including India for cost efficiency.

Full Transcript OPERATOR Good day, ladies and gentlemen, and welcome to the Medpace Hldgs second quarter 2026 earnings conference call.

At this time, all participants are in a listen-only mode.

After the speakers' remarks, there will be a question-and-answer session.

If you'd like to ask a question, please press star 11 on your phone.

If your question has been answered and you'd like to remove yourself from the queue, simply press star 11 again.

As a reminder, this call is being recorded.

I would now like to introduce your host for today's conference call, David Rue, Medpace Hldgs' Director of Investor Relations.

You may begin.

David Rue, Director of Investor Relations Good morning and thank you for joining Medpace Hldgs' second quarter 2026 earnings conference call.

Also on the call today is our CEO August Trundle and our CFO Kevin Brady.

Before we begin, I would like to remind you that our remarks and responses to your questions during this teleconference may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

These statements involve inherent assumptions with known and unknown risks and uncertainties as well as other important factors that could cause actual results to differ materially from our current expectations.

These factors are discussed in our Form 10-K and other filings with the SEC.

Please note that we assume no obligation to update forward-looking statements even if estimates change accordingly.

You should not rely on any of today's forward-looking statements as representing our views as of any date after today.

During this call we will also be referring to certain non-GAAP financial measures.

These non-GAAP measures are not superior to or a replacement for the comparable GAAP measures, but we believe these measures help investors gain a more complete understanding of results.

A reconciliation of such non-GAAP financial measures to the most directly comparable GAAP measures is available in the earnings press release and earnings call presentation slides provided in connection with today's call.

The slides are available in the Investor Relations section of our website at investor.medpace.com.

With that, I would now like to turn the call over to August Trundle.

August Trundle, CEO Good day, everyone.

The business environment was strong in Q2 2026.

Cancellations were well behaved and supported a record quarter for net bookings.

RFPs were up sequentially and year over year, generating high quality opportunities.

Initial award notifications remained solid although they declined sequentially from a very strong Q1.